Last reviewed · How we verify

NCT05125887: EVIDENCE

Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2)

Status unknown Last updated 4 May 2022
What this trial tests

trial testing Questionnaire in SARS-CoV2 Infection in 400 participants. Status unknown.

Timeline
1 February 2022
Primary endpoint
12 December 2022
12 June 2023

Quick facts

Lead sponsorUniversity Hospital, Limoges
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 February 2022
Primary completion12 December 2022
Estimated completion12 June 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Limoges

Who can join

18 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Outpatient management of patients with a milder form of COVID may be associated to an unfavorable initial or deferred course in relation to the pathology.. Outpatients represent the bulk of patients with COVID-19. To know their evolution, their secondary complications and identifying a profile of "at risk" patients is essential for the prevention and care of future non-hospitalized patients, in an epidemic context still active. This study could make it possible to redefine the follow-up of outpatients. The study consists of a simple questionnaire and possibly a teleconsultation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

Other University Hospital, Limoges trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05125887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing